Full Breakdown
Novo Nordisk Cuts Prices for Wegovy and Ozempic Amid Market Pressures
11/17/2025, 8:45:40 PM
Price Reductions Announced
Novo Nordisk, the Danish pharmaceutical company, has announced significant price reductions for its popular weight loss drug Wegovy and diabetes medication Ozempic. Effective November 17, 2025, the cash price for both medications will drop from $499 to $349 per month for self-paying patients. Additionally, new customers will be able to access the first two monthly doses of these drugs for $199, a promotional offer that will expire on March 31, 2026. The 2-milligram dose of Ozempic will remain priced at $499 per month.
Context of the Price Cuts
These price adjustments come in response to increased competition from Eli Lilly and compounding pharmacies, which have been offering lower-cost alternatives to Novo Nordisk's GLP-1 medications. The price cuts are part of a broader strategy to enhance accessibility, particularly as the Trump administration has pressured pharmaceutical companies to lower drug costs. Under a recent agreement, Medicare will cover Novo's Wegovy and Eli Lilly's Zepbound, with the aim of making these treatments more affordable for older adults.
Market Dynamics and Consumer Impact
The cash market for GLP-1 drugs, which includes Wegovy and Ozempic, accounts for approximately 10% of total prescriptions in the U.S. According to a KFF Health Tracking Poll, about 1 in 8 adults currently use these medications, with cost being a significant barrier for many. The poll indicated that nearly 25% of insured users have paid the full cost of their medications, highlighting the financial challenges associated with these treatments.
Evan Seigerman, a pharmaceutical analyst at BMO Capital Markets, noted that the new pricing is a reaction to Novo Nordisk's declining market share and aims to regain competitiveness against Eli Lilly and compounding pharmacies. The reduced prices for Wegovy and Ozempic are now more aligned with those offered by competitors, making them more accessible to consumers.
Official Statements and Responses
Dave Moore, executive vice president of U.S. operations for Novo Nordisk, emphasized the company's commitment to affordability, stating, “As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them.” He added that the price cuts are part of a larger strategy to expand access through partnerships with telehealth providers and major retailers.
Criticism and Opposition
Despite the positive reception from some healthcare professionals, there are concerns regarding the long-term sustainability of these price cuts. Critics argue that while the reductions are beneficial, they may not address the underlying issues of high list prices and limited insurance coverage for these medications. Dr. Vladimir Kushnir of BJC HealthCare remarked that lowering prices is "life-changing" for many patients, but the broader healthcare system still poses challenges for affordability.
What's Next
Looking ahead, Novo Nordisk plans to introduce oral versions of its GLP-1 medications, expected to be priced at $149 per month, pending FDA approval. The company is also working to enhance its direct-to-consumer sales channels and expand partnerships to further improve access to its medications.
Verbatim Quotes
- “There’s a lot of interest in direct pay, self-pay,” — Dave Moore, Executive Vice President, U.S. Operations, Novo Nordisk
- “The U.S. healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines,” — Dave Moore, Executive Vice President, U.S. Operations, Novo Nordisk
